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Abstract: Some lipoprotein disorders related to the residual risk of premature cardiovascular disease
(PCVD) are not detected by the conventional lipid profile. In this case-control study, the predictive
power of PCVD of serum sdLDL-C, measured using a lipoprotein precipitation method, and of
the physicochemical properties of serum lipoproteins, analyzed by nuclear magnetic resonance
(NMR) techniques, were evaluated. We studied a group of patients with a first PCVD event (n = 125)
and a group of control subjects (n = 190). Conventional lipid profile, the size and number of Very
Low Density Lipoproteins (VLDL), Low Density Lipoproteins (LDL), High Density Lipoproteins
(HDL) particles, and the number of particles of their subclasses (large, medium, and small) were
measured. Compared to controls, PCVD patients had lower concentrations of all LDL particles, and
smaller and larger diameter of LDL and HDL particles, respectively. PCVD patients also showed
higher concentrations of small dense LDL-cholesterol (sdLDL), and triglycerides (Tg) in LDL and
HDL particles (HDL-Tg), and higher concentrations of large VLDL particles. Multivariate logistic
regression showed that sdLDL-C, HDL-Tg, and large concentrations of LDL particles were the
most powerful predictors of PCVD. A strong relationship was observed between increased HDL-Tg
J. Clin. Med. 2021, 10, 1379. https://doi.org/10.3390/jcm10071379 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 1379 2 of 10
concentrations and PCVD. This study demonstrates that beyond the conventional lipid profile, PCVD
patients have other atherogenic lipoprotein alterations that are detected by magnetic resonance
imaging (MRI) analysis.
Keywords: NMR analysis of lipoproteins; lipid profile; premature cardiovascular disease; residual
cardiovascular risk; small dense LDL; lipoprotein particle number; lipoprotein precipitation
1. Introduction
Premature cardiovascular disease (PVCD) remains an important public health issue
and dyslipidemia is the most common risk factor of this condition [1] Patients with pre-
mature cardiovascular disease (PCVD) have non-conventional risk factors, both lipid and
non-lipid [2,3], which entail a residual cardiovascular risk that is usually not detected or
adequately controlled [4,5]. The Progression of Early Subclinical Atherosclerosis (PESA)
study demonstrated that subclinical atherosclerosis is present in individuals without tradi-
tional cardiovascular risk factors (CVRFs) and with Low Density Lipoprotein cholesterol
(LDL-C) at levels currently considered normal [6]. Furthermore, in the Multi-ethnic Study
of Atherosclerosis (MESA) study a lower cut-off value for LDL-C (70 mg/dL) was proposed
with which some individuals still present subclinical atherosclerosis [7]. Consequently,
new biomarkers to estimate residual cardiovascular risk must be considered. Among
them are different alterations in the number, structure, and function of plasma lipopro-
teins. Extended studies of lipid metabolism have shown that individuals with an excess
of low-density lipoprotein (LDL) particles have a higher cardiovascular risk, even when
total cholesterol and LDL-cholesterol (LDL-C) levels are within the reference range, and
this risk is higher in those with a predominance of smaller and denser LDL particles,
compared to subjects with a predominance of larger and buoyant LDL particles [5–8].
Currently, total serum cholesterol concentrations, cholesterol in LDL particles, cholesterol
in high-density lipoprotein (HDL) particles, and total serum triglycerides (Tg) constitute
the conventional lipid profile, but this profile does not allow the detection of other lipid
metabolism disorders that may predispose to PCVD [6,9]. For this reason, it is of interest
to determine the role of other lipoprotein characteristics beyond cholesterol content, such
as the cholesterol concentration of small dense LDL (sdLDL), which are not measured in
automated clinical laboratories [10,11].
To date, the reference method for the study of lipoproteins requires a centrifuga-
tion stage, which is not usually available because of its cost and lengthy time of analysis.
However, other methods have recently been developed to separate sdLDL and quan-
tify its cholesterol content. Hirano and collaborators developed a method that provides
interchangeable results with ultracentrifugation and can be easily adapted to clinical labo-
ratories [12].
Lipoproteins and their apolipoproteins may undergo alterations that affect their struc-
ture, functionality, composition, and plasma concentrations and favor their accumulation
in the arterial wall, triggering greater inflammatory and immune response and promot-
ing atherosclerosis and its complications [6,9,10]. It has been observed that among these
lipoprotein alterations, the diameter and number of particles measured by nuclear magnetic
resonance (NMR) are the most relevant for the prediction of cardiovascular risk [6,13].
In the present case-control study we explored the power of the physicochemical
properties of lipoproteins to predict PCVD to evaluate the residual cardiovascular risk
beyond c-LDL. Our hypothesis is that the advanced lipid profile may be a new reliable
biomarker of residual cardiovascular risk in patients already treated with lipid-lowering
drugs and in whom LDL-C has reduced. The final purpose of this study was to demonstrate
that lipoprotein size and its composition can be a better predictor of PCVD than LDL-C in
patients on statin therapy who have already achieved the LDL-C goal.
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2. Materials and Methods
2.1. Population
In this study a group of 125 patients who had had PCVD as the first cardiovascular
event between 1 January 2014 to 31 December 2016 were included. Patients of both sexes
less than 50 years of age were recruited from lipid and vascular risk units affiliated with the
Spanish Arteriosclerosis Society. The study protocol was approved by the Clinical Research
Ethics Committee of the Hospital de Bellvitge, and all the patients signed the informed
consent. PCVD was defined as a first episode of one of the following cardiovascular events:
Angina pectoris with signs of coronary obstruction documented by angiography, acute
myocardial infarction, stroke, transitory ischemic attack with at least one luminal stenosis
≥50% in the carotid or subclavian arteries and revascularization of any arterial territory
due to atherosclerosis. All premature cardiovascular events were confirmed with objective
data or a complementary test.
Patients with poor general health conditioning a short life expectancy, intellectual
impairment, kidney or liver failure, and other causes of secondary dyslipidemia were
excluded.
Control subjects were selected from apparently healthy workers from a car factory
paired by age and sex.
The characteristics of the two groups are described in Table 1.
Table 1. Clinical data of patients and control subjects.
Variables (Units) Control Groupn = 190
PCVD Group
n = 125
Age (years) 47 (3.7) 46.5 (4.4)
Male (%) 150 (78.9%) 99 (79.2%)
Coronary artery disease - 79 (63.2%)
Stroke or TIA - 46 (36.8%) a
BMI (kg/m2) 26.7(3.6) 29 (4.98) a
Diabetes mellitus 3 (1.6%) 16 (12.8%) a
Hypertension 22 (11.6%) 48 (38.4%)
Smoking 59 (31%) 32 (25.6%)
Lipid-lowering drugs 20 (10.5%) 116 (92.8%) a
Anti-platelet drugs 3 (1.6%) 118 (94.4%) a
Cholesterol (mg/dL) 207.4 (33.3) 155.3 (40.8) a
HDL-Cholesterol (mg/dL) 56.8 (12.4) 44.5 (14.8) a
Triglycerides (mg/dL) 121.1 (98.6) 140.6 (99.6)
LDL-C (mg/dL) 144.38 (12.5) 96.49 (7.9) a
Data are expressed as mean (standard deviation) or case number (percentage). PCVD: Premature cardiovascular
disease; TIA: Transitory ischemic attack; SBP: Systolic blood pressure; HDL-Cholesterol: High-density lipoprotein
cholesterol, LDL-C: Low density lipoprotein-cholesterol. (a) indicates differences between groups with p < 0.05.
2.2. Variables Included
Lipid variables from the conventional lipid profile were evaluated, including plasma
cholesterol concentrations, Tg, LDL-C, and HDL-C. Extended lipid profile biomarkers were:
sdLDL-C, very low density lipoprotein cholesterol (VLDL-C), VLDL-Tg, VLDL particle
number (VLDL-P) including small (sVLDL-P), medium (mVLDL-P), and large (lVLDL-P),
VLDL diameter (VLDL-Z), intermediate density lipoprotein cholesterol (IDL-C), IDL-Tg,
LDL-Tg, LDL particle number (LDL-P) including small (sLDL-P), medium (mLDL-P), and
large (lLDL-P), LDL diameter (LDL-Z), HDL-Tg, HDL particle number (HDL-P) including
small (sHDL-P), medium (mHDL-P), and large (lHDL-P), and HDL diameter (HDL-Z).
2.3. Sample Collection
PCVD group samples: Venous blood samples were withdrawn after a 12-h overnight
fast. All serum samples were collected in tubes without anticoagulant and with separating
gel. Serum samples were conserved at −80 ◦C until analysis.
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Control group samples: Venous blood samples were withdrawn after a 12-h overnight
fast. Plasma was collected in tubes containing the anticoagulant EDTA-K3 (BD, Vacutainer,
NJ, US) and were centrifuged immediately for 15 min at 1500 g and at 4 ◦C. The plasma
was immediately separated and stored at −80 ◦C until biochemical and NMR analysis.
2.4. Methods
2.4.1. Lipoprotein Precipitation Techniques
sdLDL-C concentrations were obtained using a specific lipoprotein precipitation
method previously described by our group and adapted for use in routine clinical labo-
ratories. G centrifugation force and cooling samples temperature were modified in order
to improve lipoprotein precipitation with a density <1.044 g/mL in hypertriglyceridemic
samples [14].
2.4.2. Nuclear Magnetic Resonance (NMR) Analysis
Before 1H-NMR analysis, 200 µL of serum were diluted with 50 µL deuterated water
and 300 µL of 50 mM phosphate buffer solution (PBS) at pH 7.4. 1H-NMR spectra were
recorded at 310 K on a Bruker Avance III 600 spectrometer (Bruker BioSciences Española
S.A., Rivas Vaciamadrid, Madrid, Spain) operating at a proton frequency of 600.20 MHz
(14.1 T) as previously reported [15].
The Liposcale® test was used to obtain the whole lipoprotein profile including lipid
concentrations, Tg and cholesterol, size and particle number of three VLDL, LDL, and HDL,
as well as the particle number of nine subclasses (large, medium, and small VLDL, LDL, and
HDL). Particle concentrations and diameter were obtained from the measured amplitudes
of the methyl group NMR signals that differ among the lipoprotein subclasses [15].
2.5. Statistical Analysis
Descriptive analysis of the advanced lipoprotein panel of the two groups was per-
formed. Results are shown as medians and 25th and 75th percentiles and comparative
analyses of the variable medians between groups were performed using the Mann–Whitney
U test.
The statistical approach consisted in different steps:
First, a logistic univariate regression analysis was carried out to explain the contribu-
tion between each variable and the development of PCVD. The results of each variable and
its p-value are shown in Table S1.
Secondly, Spearman correlation rho were calculated for variables with p < 0.05 in
the univariate analysis that were significantly related to PCVD.
Among the pairs of variables presenting rho > 0.5, the variable with the lowest
significance in the univariate analysis was not considered for the final model.
The model selected is the one which presents the highest goodness-of-fit evaluated
with the most significant Hosmer–Lesmeshow index (HL) and the highest diagnostic
accuracy calculated by receiver operating curve (ROC) analysis. The p-value and pseudo-
R2 de Nagelkerke of the model were estimated and odds ratios (OR) of each variable
included in the model were calculated.
In addition, ROC analysis was performed. The area under the curve (AUC), and
the sensitivity and specificity of the model were estimated in order to establish the efficiency
of the model for PCVD prediction. Contributions of each variable to the risk of presenting
a premature ischemic event were evaluated taking into account the OR results obtained
in the logistic regression. The ROC analysis was also cross validated to avoid the risk of
over-fitting and to increase the predictive capacity using the Venetian blinds method.
Stata® 14 software (StataCorp LLC, College Station, TX, USA) was used to carry out
the statistical analyses.
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3. Results
Table 2 shows the advanced lipoprotein data of the two groups. Patients with PCVD
presented lower concentrations of large, medium, and small sized LDL particles compared
to controls. In the PCVD group, the LDL particle diameter was smaller and sdLDL-C and
LDL-Tg concentrations were higher. Large-VLDL particles concentration was also higher
in patients with PCVD. HDL-Tg concentrations were higher and had a larger diameter
in PCVD patients compared to controls. Only variables showing significant differences
between groups were evaluated for inclusion in the multivariate logistic regression model.
After that the collinearity study was carried out. The variables excluded were those
that correlated with HDL-Tg (p = 1.35 × 10−25) as follows: lHLDL-P (p = 3.25 × 10−11)
rho = 0.471; mHLDL-P (p = 2.95 × 10−7) rho = 0.537; sHDL-P (p = 0.001) rho = 0.157;
HDL-Z (p = 1.30 × 10−10) rho = 0.199; lVLDL-P (0.001) rho= 0,654; LDL-P (p = 7.31 × 10−13)
rho = 0.385; mLDL-P (p = 2.41 × 10−13) rho = 0.485; sLDL-P (p = 1.30 × 10−8) rho = 0.272;
LDL-Z (p = 1.02 × 10−9) rho = 0.267; LDL-C (p = 2.90 × 10−13) rho = 0.469.
Variables that were candidates for the final model were: sdLDL-C, lLDL-P, HDL-Tg,
VLDL-Z, LDL-Tg. According to the highest goodness-of-fit and the highest diagnostic
accuracy calculated by a ROC curve analysis, the model selected included sdLDL-C, lLDL-P,
HDL-Tg.
Table 2. Comparison between the advanced lipoprotein panels of the two groups.
Variables (Units) Control Group(n = 190)
PCVD Group
(n = 125) p Value
Very Low Density Lipoprotein
Cholesterol (mg/dL) 12.27 (6.90–21.16) 14.21 (8.44–19.94) 0.173
Triglycerides (mg/dL) 56.72 (33.74–82.68) 61.15 (43.67–92.71) 0.06
Total particles (nmol/L) 41.22 (23.86–62.63) 41.57 (30.93–64.28) 0.143
Large particles (nmol/L) 0.85 (0.53–1.29) 1.27 (0.94–1.76) <0.0001
Medium particles (nmol/L) 4.57 (3.05–6.39) 5.04 (3.21–8.13) 0.245
Small particles (nmol/L) 36.00 (20.21–54.55) 35.11 (27.05–55.86) 0.138
Diameter (nm) 42.13 (42.01–42.25) 42.28 (42.14–42.43) <0.0001
Intermediate Density Lipoprotein
Cholesterol (mg/dL) 8.16 (5.53–11.05) 9.07 (7.22–11.43) 0.074
Triglycerides (mg/dL) 10.05 (7.91–12.96) 9.81 (8.27–11.60) 0.683
Low Density Lipoprotein
Cholesterol (mg/dL) 144.38 (134.08–169.37) 96.49 (83.14–112.22) <0.0001
Triglycerides (mg/dL) 19.27 (11.61–23.86) 12.07 (9.66–15.01) <0.0001
Total particles (nmol/L) 1457.93 (1312.05–1648.66) 994.78 (880.20–1144.72) <0.0001
Large particles (nmol/L) 221.12 (186.67–238.65) 158.76 (139.20–175.46) <0.0001
Medium particles (nmol/L) 519.99 (422.60–605.56) 246.81 (187.99–308.80) <0.0001
Small particles (nmol/L) 724.35 (642.38–861.24) 587.73 (532.41–671.76) <0.0001
Cholesterol small particles (mmol/L) 320.00 (180.15–460.06) 420.38 (265.28–704.79) <0.0001
Diameter (nm) 21.16 (20.99–21.33) 20.91 (20.78–21.06) <0.0001
High Density Lipoprotein
Cholesterol (mg/dL) 48.86 (38.76–57.78) 45.47(39.92–51.72) 0.101
Triglycerides (mg/dL) 7.88 (6.07–9.85) 14.61(11.41–17.52) <0.0001
Total particles (µmol/L) 24.78 (20.18–28.12) 24.18 (21.05–27.86) 0.855
Large particles (µmol/L) 0.23 (0.19–0.27) 0.26 (0.24–0.30) <0.0001
Medium particles (µmol/L) 6.80 (5.66–8.69) 9.02 (7.93–10.43) <0.0001
Small particles (µmol/L) 16.83 (13.93–19.34) 14.98 (12.08–17.57) 0.003
Diameter (µmol/L) 8.21 (8.17–8.25) 8.30 (8.24–8.34) <0.0001
Data are expressed as medians (interquartile interval).
After discarding covariances, the most powerful biomarkers that could contribute
to predicting PCVD were sdLDL-C, HDL-Tg, and lLDL-P. Table 3 shows the results of
the multivariate logistic regression analysis and the ORs of the model. Logistic regression
was statistically significant with a p < 0.001 and a pseudo-R2 of Nagelkerke = 0.73.
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Table 3. Results of the multivariate logistic regression analysis.
Variables (Units) OR [CI 95%] p Value R2
Constant 27.367 1.650 to 453.845 0.021 0.730
sdLDL-C (mmol/L) 1.002 1.000 to 1.003 0.030
HDL-Tg (mg/dL) 1.622 1.296 to 1.764 <0.0001
lLDL-P (nmol/L) 0.956 0.941 to 0.967 <0.0001
OR (odds ratio); [CI 95%] (95% confidence interval); R2 (pseudo-R2 of Nagelkerke), sdLDL-C (small dense
LDL-cholesterol); HDL-Tg (HDL-triglyceride); lLDL-P (large LDL particle number).
The ORs of each variable indicate the risk of presenting a premature ischemic event
caused by this variable. All variables included in the logistic regression contributed
significantly to the risk of PCVD with a p < 0.05. A strong relationship was observed
between the increase in HDL-Tg concentrations and PCVD.
The diagnostic accuracy of the model to predict PCVD was estimated using ROC
analysis (Figure 1). The AUC obtained and its 95% confidence interval (CI) was 0.95
(0.92–0.99). The sensitivity was 94.7% and the specificity was 80.3%. The ROC analysis was
cross-validated to avoid the risk of over-fitting and to increase the predictive capacity using
the Venetian blinds method. The AUC remained unaltered (<1%) after the cross-validation
process.
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4. Discussion
There is a need to characterize the residual risk of PCVD patients without dyslipi-
demia in the conventional lipid profile [16,17]. Several studies have shown that obtaining
the lipoprotein profile by NMR in these patients could help to predict the risk of car-
diovascular disease [18–20]. Although the independence of NMR lipid variables versus
traditional lipid profile has not been demonstrated, there are some studies that support
the superiority of advanced lipid profile in estimating cardiovascular risk [21–23]. In this
prospective observational study, we evaluated the contribution of advanced lipid profile
parameters in a multivariate logistic regression model for PCVD prediction. NMR study
of the lipoprotein profile (Liposcale® test) consists in the mathematical deconvolution
of the various resonance signals given by the methyl groups of the lipoprotein lipid nu-
cleus [16]. The Liposcale® test analyzes the average diameter, cholesterol and Tg content,
and concentrations of the number of VLDL, LDL, and HDL lipoproteins, and the content
of Tg and cholesterol of IDL particles and the concentration of the number of VLDL, LDL,
and HDL lipoprotein subclasses (large, medium, and small).
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We found significant differences between groups in the different subclasses of lipopro-
teins, including their diameter and composition. LDL-P and LDL-C were significantly
lower in PCVD patients than in control subjects which may be the consequence of a higher
use and intensity of lipid-lowering treatments in PCVD patients. However, it should be
noted that neither of these two variables were included in the predictive model.
Particle diameter is one of the main lipoprotein characteristics that influences athero-
genicity. It has been observed that smaller LDL and VLDL are more atherogenic because
they are more easily retained in the endothelium [24,25]. However, the exception to this
are large buoyant VLDL (lVLDL-P) which are more atherogenic since their metabolism
generates sdLDL particles that are more atherogenic than large buoyant LDL particles
which are formed from small VLDL particles. In the present study, PCVD patients had
higher concentrations of lVLD-P and sdLDL particles, and sdLDL-C than control subjects.
It is well known that cholesterol contained in small LDL particles is more atherogenic,
since it is directly related to the thickening of the intima media [9,19] and to a higher risk of
cardiovascular disease. However, there is also evidence that in some patients with coronary
disease large LDL particles predominate compared to other LDL subclasses. In addition, it
has been observed that large LDL is an independent determinant of carotid intima media
thickness (cIMT) in healthy men, and in the MESA study [6] both large LDL and small LDL
particle numbers correlated with cIMT.
In the multivariate logistic regression model of the present study only three biomarkers
were significantly associated with PCVD: sdLDL-C, HDL-Tg, and large LDL-P. These
variables explained 72% of PCVD risk. The role of HDL-Tg in this model is especially
relevant because an increase of 1 mg/dL in serum HDL-Tg was associated with an increase
in PCVD risk of 62%. On the other hand, an increase of 1 mmol/L in the number of
large LDL particles was associated with a decrease of 4.4% in PCDV risk, whereas the
effect of sdLDL-C on PCVD risk, although significant, was small. This model presented a
high AUC with good sensitivity suggesting that it could be used for PCVD risk screening,
especially in subjects with first-degree relatives with cardiovascular disease who have low
LDL concentrations, or in patients with cardiovascular disease that is not explained by
traditional biomarkers and in whom additional residual risk must be considered. These
data agree with those from other studies and support the contention that NMR lipoprofile
biomarkers are stronger predictors of PCVD [26] and subclinical atherosclerosis [27] than
other conventional risk factors such as LDL-C concentrations.
The role of HDL-Tg as a predictor of PCVD risk may be explained by the decrease in
the antiatherogenic properties of HDL that has been observed as these particles become
enriched in Tg [28,29].
On the other hand, the value of HDL particle diameter as a predictive factor of CVD is
controversial. Some studies demonstrate that HDL-P and SHDL-P are inversely related to
CVD [30,31] and to all-cause as well as cardiovascular mortality in CAD patients [32]. In
our study patients in the PCVD group had a higher number of large HDL particles and a
smaller number of small HDL particles than the control group.
The number of LDL particles can also be estimated quantifying plasma Apo B concen-
trations, since every LDL particle contains only one Apo B molecule. Some studies have
shown that Apo B is a more powerful marker of cardiovascular disease risk than LDL-c
and non HDL-C [33]. In addition, in other studies the increased atherogenic effect of small
LDL particles has not been observed, and the number of both total LDL and HDL particles
has been described as a better predictor of cardiovascular risk. In fact, it has been reported
that a percentage greater than 65% of the interindividual differences in cardiovascular risk
is due to the number of lipoprotein particles and not to the diameter [34].
The discordance between LDL-C and advanced lipid profile data is mainly observed
in individuals at risk of cardiovascular disease presenting high Tg concentrations, type
2 diabetes mellitus or metabolic syndrome (MS) [35]. MS patients present the highest
prevalence of Tg, sdLDL particles, and large HDL particles.
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The results of this study show that beyond the conventional lipid profile, the NMR
advanced lipid profile can detect other lipoprotein alterations related to the residual risk of
PCVD. Some clinical guidelines recommend the measurement of LDL-P concentrations
in the follow-up of patients with MS [36] and type 2 diabetes mellitus [37]. Some expert
panels and international guidelines propose to guide lipid-lowering therapy based on
LDL-P concentrations instead of LDL-C concentrations, establishing a discriminant value
of LDL-P <1000 nmol/L [38].
As we have hypothesized, PCVD individuals that were on statin therapy, and whose
LDL-C values were lower than those of control subjects, had a higher concentration of
sdLDL-C. These results support the relevance of LDL cholesterol composition and size on
PCVD progression and its potential as a new biomarker for residual cardiovascular risk.
This study has several limitations. Lp(a) measures were not considered in this study
as the control group was recruited in primary care centers where this determination is
not available. Lastly, these hypothesis-generating findings warrant further studies as no
independent validation has been done.
5. Conclusions
Beyond the conventional lipid profile, PCVD patients have other atherogenic lipopro-
tein alterations that are not detected by the conventional lipid profile. The study of lipopro-
teins by NMR may allow the detection of these alterations and a broader understanding of
the vascular risk related to dyslipidemias.
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